Aquinox Pharmaceuticals Inc. shares AQXP, -0.65% slid 73% in premarket trade Wednesday, after the Canadian-based biotech said a trial of a treatment for cystitis and severe bladder pain syndrome failed to meet its main goal. “This is a disappointing result for Aquinox and for patients,” Chief Executive David Mai said in a statement. The trial, called LEADERSHIP 301, “was a robust and well-conducted trial, and we believe the results are definitive.” The company said the results support halting all further development, but it plans to review its pipeline and provide further guidance later this year. The trial involved 433 participants who received Aquinox’s once-daily, oral rosiptor, or AQX-1125, or placebo. It failed to achieve a statistically significant reduction in mean change from Baseline at Week 12 in maximum daily bladder pain score inthe female patients, which was its primary endpoint. The company will host a conference call at 8.30 a.m. ET Wednesday. Shares have gained 30% in 2018 through Tuesday, while the S&P 500 SPX, +0.22% has gained 1.9%.